With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

According to TipRanks.com, Richter is a 4-star analyst with an average return of 8.8% and a 42.9% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ultragenyx ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

When COVID-19 cases were surging, Dr. David Wohl saw patients “hungry for air” fill UNC hospital wards. What most saved lives ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...

RNA expert Jeff Coller spoke with Live Science about the future of mRNA vaccines in the United States in the aftermath of ...

The Nobel Prize winning scientist behind mRNA vaccine technology has attacked the US health secretary’s plan to effectively ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...